Results

Total Results: 2,146 records

Showing results for "factor".

61. Computerized Definitions Showed High Positive Predictive Values for Identifying Reasons for Hospitalizations in a Medicaid Population with Rheumatoid Arthritis (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-hospitalizations_research.pdf
    October 01, 2008 - for post marketing studies of medication safety and we are evaluating the safety of tumor necrosis factor … bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor … Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor … Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go … opportunistic infections and other serious potential adverse events associated with tumor necrosis factor

62. Rheumatoid-Arthritis-Medicine Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_surveillance.pdf
    March 01, 2013 - Oral DMARDs Anti-­‐tumor  necrosis  factor  drugs  vs.   … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Oral DMARDs Anti-tumor necrosis factor drugs vs.

63. Rheumatoid-Arthritis-Medicine Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine_surveillance.pdf
    March 01, 2013 - Oral DMARDs Anti-­‐tumor  necrosis  factor  drugs  vs.   … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Oral DMARDs Anti-tumor necrosis factor drugs vs. … Oral DMARDs Anti-tumor necrosis factor drugs vs.

64. Detection of Associations Between Trial Quality and Effect Sizes | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/trial-quality-effect-association/research
    January 05, 2012 - trial results in meta-analyses, the amount of additional heterogeneity in effect sizes is a crucial factor

65. Blood-Clots-Hip-Knee-Surgery Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/blood-clots-hip-knee-surgery_executive.pdf
    March 01, 2012 - Classes include oral antiplatelet agents, injectable LMWHs, injectable UFH, injectable or oral factor … factor Xa inhibitors vs. … LMWHs may be inferior to factor Xa inhibitors in terms of any, proximal, and distal DVTs but have a … As such, it is likely inferior to factor Xa inhibitors in the balance of benefits and harms as well … VKAs but higher bleeding; worse efficacy vs. factor Xa inhibitors but lower bleeding).

66. Evidence Report on the (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/crohns-disease_research-protocol.pdf
    September 01, 2010 - antibodies, monoclonal/adverse effects”[mh] OR “anti-inflammatory agents”[mh] OR ((“tumour necrosis factor … ”[tiab] OR “tumour necrosis factor-alpha”[tiab] OR “tumor necrosis factor”[tiab] OR “tumor necrosis … factor-alpha”[tiab] OR TNF[tiab] OR TNF- alpha[tiab]) AND (antibod*[tiab] OR antagonist[tiab] OR antagonists … Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy … KQ = Key question NMA = network meta-analysis RCT = randomized control trial TNF = tumor necrosis factor

67. Asthma-Immunotherapy-2011 Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/asthma-immunotherapy-2011_research.pdf
    January 01, 2011 - The checklist for risk factor studies had 26 subjects and nine response categories. … Factor _________ known gold standard _________ Loss of followup. … Define risk factor or list risk factors for which quality assessment would be the same. … measure exposure Hypothesis specific: complete for each risk factor. … Hypothesis specific: complete for each risk factor. Validation.

68. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0496_12-30-2011.pdf
    January 01, 2011 - The most important risk factor for CIN, chronic kidney disease, is rising, driven in part by the increasing

69. Disposition of Comments Report for Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_disposition-comments.pdf
    March 07, 2012 - Disposition of Comments Report for Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated … Research Review Disposition of Comments Report Research Review Title: Antinuclear Antibody, Rheumatoid Factor … Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal … Similarly, I am not sure that the authors are familiar with modern tests for rheumatoid factor.

70. Decisional Dilemmas in Discontinuing Prolonged Disease-Modifying Treatment for Multiple Sclerosis | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/multiple-sclerosis/research
    April 28, 2015 - who were considering pregnancy or already pregnant or patients discontinuing natalizumab due to risk factor

71. Topic Suggestion Description | Effective Health Care Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/anesthesia
    May 01, 2021 - In relation to Covid: research also shows the #1 associated risk factor of Ventilator Associated Pneumonia … It is unknown why the short time frames had ever been imposed for an intubation to be the etiologic factor … LOW cuff pressure is the #1 associated factor of Ventilator Associated Pneumonia (VAP) allowing for increased … ……This impairment of tracheal mucosal blood flow is important factor in tracheal morbidity associated

72. Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/musculoskeletal-complaints-tests-children/

73. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-natriuretic-peptide_research-protocol.pdf
    December 20, 2011 - -32.mp. 7 bnp77-108.mp. 8 probnp.mp. 9 nt-probnp1-76.mp. 10 natriuretic factor … -32.tw. 7 bnp77-108.tw. 8 probnp.tw. 9 nt-probnp1-76.tw. 10 natriuretic factor … -32.tw. 7 bnp77-108.tw. 8 probnp.tw. 9 nt-probnp1-76.tw. 10 natriuretic factor … Prognostic Factor Measurement 3. … The prognostic factor of interest is adequately measured in study participants to sufficiently limit

74. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0075_03-10-2009.pdf
    January 01, 2009 - Aminosalicylates, corticosteroids, immune system suppressors, antibiotics, anti-diarrheals, anti-tumor necrosis factor

75. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0405_01-16-2011.pdf
    January 01, 2011 - Cough is also an important factor in the spread of infectious disease.

76. 08 Functional Limitations Potential High Impact 2012-12-10 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/08_functional_limitations_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - Current therapies, specifically human factor VIIa (NovoSeven ® ) and Feiba ™ , work by bypassing the … VIII product that serves as factor VIII replacement therapy by activating the natural coagulation … OBI-1 is an intravenous, recombinant, porcine factor VIII product that serves as factor VIII replacement … reducing immunogenicity of the antigen to recombinant porcine factor VIII. … Study of modified recombinant factor VIII (OBI-1) in subjects with congenital hemophilia A.

77. Assessing the Impact of Economic Evidence on Policymakers in Health Care — A Systematic Review | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/economic-evidence/research
    October 23, 2012 - evidence: (1) quality and transparency of the studies that provided the economic evidence was a promoting factor

78. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-2007_executive.pdf
    January 01, 2007 - Three biologics (adalimumab, etanercept, and infliximab) are also classified as anti-tumor necrosis factor … elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor … Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor … Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients … Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor

79. The Effectiveness of Disease-Modifying Antirheumatic Drugs (DMARDS) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards/research-protocol
    March 09, 2010 - Polyarthritis: affects five or more joints during the first 6 months of disease; is subclassified as rheumatoid factor-negative … and rheumatoid factor-positive disease, the latter of which may be associated with more destructive … nephrotoxicity hepatotoxicity D-Penicillamine Depen Cuprimine unknown (may lower IgM rheumatoid factor … sensitivity analyses include: study quality, including the quality of the measurement of exposure to the factor … Settings RCTs Randomized Controlled Trials TEP Technical Expert Panel TNF Tumor Necrosis Factor

80. Stroke Prevention in Atr ial Fibr illation Patients: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-afib-update_research-protocol-amended.pdf
    October 27, 2017 - Newer anticoagulants (direct oral anticoagulants [DOACs]) • Direct thrombin Inh-DTI: Dabigatran • Factor … Inhibitors"[Mesh] OR "Anticoagulants"[Pharmacological Action] OR "Factor Xa Inhibitors"[Pharmacological … Xa inhibitor"[tiab] OR "factor Xa inhibitors"[tiab] OR "Blood clotting inhibitor"[tiab] OR "blood … Inhibitors"[Mesh] OR "Anticoagulants"[Pharmacological Action] OR "Factor Xa Inhibitors"[Pharmacological … Xa inhibitor"[tiab] OR "factor Xa inhibitors"[tiab] OR "Blood clotting inhibitor"[tiab] OR "blood